Last reviewed · How we verify
Sotagliflozin High Dose
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, which helps to reduce glucose reabsorption in the kidneys and intestines.
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, which helps to reduce glucose reabsorption in the kidneys and intestines. Used for Type 1 diabetes, Type 2 diabetes.
At a glance
| Generic name | Sotagliflozin High Dose |
|---|---|
| Sponsor | University of California, San Diego |
| Drug class | SGLT2 inhibitor |
| Target | SGLT1 and SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT1 and SGLT2, sotagliflozin increases urinary glucose excretion, leading to improved glycemic control in patients with diabetes. This mechanism of action also has potential benefits for cardiovascular outcomes.
Approved indications
- Type 1 diabetes
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Ketoacidosis
Key clinical trials
- CKM For Safe Use of SGLT2i in Type 1 Diabetes (PHASE3)
- Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sotagliflozin High Dose CI brief — competitive landscape report
- Sotagliflozin High Dose updates RSS · CI watch RSS
- University of California, San Diego portfolio CI